Literature DB >> 31669063

Program cost analysis of influenza vaccination of health care workers in Albania.

Sarah Wood Pallas1, Albana Ahmeti2, Winthrop Morgan3, Iria Preza2, Erida Nelaj2, Malembe Ebama4, Ann Levin3, Kathryn E Lafond5, Silvia Bino2.   

Abstract

BACKGROUND: Since 2012, WHO has recommended influenza vaccination for health care workers (HCWs), which has different costs than routine infant immunization; however, few cost estimates exist from low- and middle-income countries. Albania, a middle-income country, has self-procured influenza vaccine for some HCWs since 2014, supplemented by vaccine donations since 2016 through the Partnership for Influenza Vaccine Introduction (PIVI). We conducted a cost analysis of HCW influenza vaccination in Albania to inform scale-up and sustainability decisions.
METHODS: We used the WHO's Seasonal Influenza Immunization Costing Tool (SIICT) micro-costing approach to estimate incremental costs from the government perspective of facility-based vaccination of HCWs in Albania with trivalent inactivated influenza vaccine for the 2018-19 season based on 2016-17 season data from administrative records, key informant consultations, and a convenience sample of site visits. Scenario analyses varied coverage, vaccine presentation, and vaccine prices.
RESULTS: In the baseline scenario, 13,377 HCWs (70% of eligible HCWs) would be vaccinated at an incremental financial cost of US$61,296 and economic cost of US$161,639. Vaccine and vaccination supplies represented the largest share of financial (89%) and economic costs (44%). Per vaccinated HCW financial cost was US$4.58 and economic cost was US$12.08 including vaccine and vaccination supplies (US$0.49 and US$6.76 respectively without vaccine and vaccination supplies). Scenarios with higher coverage, pre-filled syringes, and higher vaccine prices increased total economic and financial costs, although the economic cost per HCW vaccinated decreased with higher coverage as some costs were spread over more HCWs. Across all scenarios, economic costs were <0.07% of Albania's estimated government health expenditure, and <5.07% of Albania's estimated immunization program economic costs.
CONCLUSIONS: Cost estimates can help inform decisions about scaling up influenza vaccination for HCWs and other risk groups. Published by Elsevier Ltd.

Entities:  

Keywords:  Cost analysis; Economic evaluation; Health care workers; Influenza; Low- and middle-income countries

Year:  2019        PMID: 31669063     DOI: 10.1016/j.vaccine.2019.10.027

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Engineering a self-navigated MnARK nanovaccine for inducing potent protective immunity against novel coronavirus.

Authors:  Yaling Wang; Yuping Xie; Jia Luo; Mengyu Guo; Xuhao Hu; Xi Chen; Ziwei Chen; Xinyi Lu; Lichun Mao; Kai Zhang; Liangnian Wei; Yunfei Ma; Ruixin Wang; Jia Zhou; Chunyan He; Yufang Zhang; Ye Zhang; Sisi Chen; Lijuan Shen; Yun Chen; Nasha Qiu; Ying Liu; Yanyan Cui; Guoyang Liao; Ye Liu; Chunying Chen
Journal:  Nano Today       Date:  2021-03-19       Impact factor: 20.722

Review 2.  WHO-led consensus statement on vaccine delivery costing: process, methods, and findings.

Authors:  Laura Boonstoppel; Logan Brenzel; Ulla Griffiths; Raymond Hutubessy; Mark Jit; Vittal Mogasale; Sarah Pallas; Stephen Resch; Christian Suharlim; Karene Hoi Ting Yeung; Ann Levin
Journal:  BMC Med       Date:  2022-03-08       Impact factor: 8.775

3.  Hesitancy toward Childhood Vaccinations: Preliminary Results from an Albanian Nursing Staff's Investigation.

Authors:  Enkeleda Gjini; Mariachiara Carestia; Fabian Cenko; Daniele Di Giovanni; Irsida Mehmeti; Stefania Moramarco; Alban Yulli; Ersilia Buonomo
Journal:  Nurs Res Pract       Date:  2022-09-09

Review 4.  Costs of seasonal influenza vaccination in South Africa.

Authors:  Heather Fraser; Winfrida Tombe-Mdewa; Ciaran Kohli-Lynch; Karen Hofman; Stefano Tempia; Meredith McMorrow; Philipp Lambach; Wayne Ramkrishna; Cheryl Cohen; Raymond Hutubessy; Ijeoma Edoka
Journal:  Influenza Other Respir Viruses       Date:  2022-03-30       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.